Advertisement

Lipoxins: update and impact of endogenous pro-resolution lipid mediators

  • S. J. O'Meara
  • K. Rodgers
  • C. Godson
Chapter
Part of the Reviews of Physiology, Biochemistry and Pharmacology book series (REVIEWS, volume 160)

Abstract

Lipoxins (LXs) are endogenously produced eicosanoids that are typically generated by transcellular biosynthesis. These trihydroxytetraene-containing lipid mediators and their stable synthetic analogues possess a wide spectrum of anti-inflammatory and pro-resolution bioactions both in vitro and in vivo. More recently, LXs have emerged as potential anti-fibrotic mediators that may influence pro-fibrotic cytokines and matrix-associated gene expression in response to platelet-derived growth factor (PDGF). Here we review the biosynthesis, metabolism and bioactions of LXs and LX analogues and their therapeutic potential.

Keywords

Chronic Obstructive Pulmonary Disease Mesangial Cell ECV304 Cell Tissue Factor Activity Mesangial Cell Proliferation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Work in the authors' laboratory is supported by the Health Research Board, Ireland, Enterprise Ireland, The Welcome Trust, European Commission FP6 funding (LSHM-CT-2004-005033), and The Government of Ireland Programme for Research in Third Level Institutions.

References

  1. Abboud HE (1995) Role of platelet-derived growth factor in renal injury. Annu Rev Physiol 57:297–309PubMedGoogle Scholar
  2. Aliberti J (2005) Host persistence: exploitation of anti-inflammatory pathways by Toxoplasma gondii. Nat Rev Immunol 5:162–170PubMedGoogle Scholar
  3. Aliberti J, Serhan C, Sher A (2002) Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J Exp Med 196:1253–1262PubMedGoogle Scholar
  4. Arita M, Oh SF, Chonan T, Hong S, Elangovan S, Sun YP, Uddin J, Petasis NA, Serhan CN (2006) Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions. J Biol Chem 281:22847–22854PubMedGoogle Scholar
  5. Badr KF, DeBoer DK, Schwartzberg M, Serhan CN (1989) Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells: evidence for competition at a common receptor. Proc Natl Acad Sci USA 86:3438–3442PubMedGoogle Scholar
  6. Bafica A, Scanga CA, Serhan C, Machado F, White S, Sher A, Aliberti J (2005) Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J Clin Invest 115:1601–1606PubMedGoogle Scholar
  7. Bannenberg GL, Aliberti J, Hong S, Sher A, Serhan C (2004) Exogenous pathogen and plant 15-lipoxygenase initiate endogenous lipoxin A4 biosynthesis. J Exp Med 199:515–523PubMedGoogle Scholar
  8. Bazan HE (2005) Cellular and molecular events in corneal wound healing: significance of lipid signalling. Exp Eye Res 80:453–463PubMedGoogle Scholar
  9. Bonnans C, Chanez P, Chavis C (2004) Lipoxins in asthma: potential therapeutic mediators on bronchial inflammation? Allergy 59:1027–1041PubMedGoogle Scholar
  10. Bonnans C, Fukunaga K, Levy MA, Levy BD (2006) Lipoxin A(4) regulates bronchial epithelial cell responses to acid injury. Am J Pathol 168:1064–1072PubMedGoogle Scholar
  11. Brady HR, Persson U, Ballermann BJ, Brenner BM, Serhan CN (1990) Leukotrienes stimulate neutrophil adhesion to mesangial cells: modulation with lipoxins. Am J Physiol 259:F809–815PubMedGoogle Scholar
  12. Brezinski ME, Serhan CN (1990) Selective incorporation of (15S)-hydroxyeicosatetraenoic acid in phosphatidylinositol of human neutrophils: agonist-induced deacylation and transformation of stored hydroxyeicosanoids. Proc Natl Acad Sci USA 87:6248–6252PubMedGoogle Scholar
  13. Cezar-de-Mello PF, Nascimento-Silva V, Villela CG, Fierro IM (2006) Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly. Oncogene 25:122–129PubMedGoogle Scholar
  14. Chiang N, Fierro IM, Gronert K, Serhan CN (2000) Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J Exp Med 191:1197–1208PubMedGoogle Scholar
  15. Chiang N, Takano T, Arita M, Watanabe S, Serhan CN (2003) A novel rat lipoxin A4 receptor that is conserved in structure and function. Br J Pharmacol 139:89–98PubMedGoogle Scholar
  16. Chiang N, Hurwitz S, Ridker PM, Serhan CN (2006) Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: a randomized human trial. Arterioscler Thromb Vasc Biol 26:e14–17PubMedGoogle Scholar
  17. Claria J, Serhan CN (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 92:9475–9479PubMedGoogle Scholar
  18. Clish CB, O'Brien JA, Gronert K, Stahl GL, Petasis NA, Serhan CN (1999) Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc Natl Acad Sci USA 96:8247–8252PubMedGoogle Scholar
  19. Clish CB, Levy BD, Chiang N, Tai HH, Serhan CN (2000) Oxidoreductases in lipoxin A4 metabolic inactivation: a novel role for 15-onoprostaglandin 13-reductase/leukotriene B4 12-hydroxydehydrogenase in inflammation. J Biol Chem 275:25372–25380PubMedGoogle Scholar
  20. Colgan SP, Serhan CN, Parkos CA, Delp-Archer C, Madara JL (1993) Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J Clin Invest 92:75–82PubMedGoogle Scholar
  21. Cybulsky AV (2000) Growth factor pathways in proliferative glomerulonephritis. Curr Opin Nephrol Hypertens 9:217–223PubMedGoogle Scholar
  22. Devchand PR, Schmidt BA, Primo VC, Zhang QY, Arnaout MA, Serhan CN, Nikolic B (2005) A synthetic eicosanoid LX-mimetic unravels host-donor interactions in allogeneic BMT-induced GvHD to reveal an early protective role for host neutrophils. FASEB J 19:203–210PubMedGoogle Scholar
  23. Edenius C, Haeggstrom J, Lindgren JA (1988) Transcellular conversion of endogenous arachidonic acid to lipoxins in mixed human platelet-granulocyte suspensions. Biochem Biophys Res Commun 157:801–807PubMedGoogle Scholar
  24. Elson CO, Sartor RB, Tennyson GS, Riddell RH (1995) Experimental models of inflammatory bowel disease. Gastroenterology 109:1344–1367PubMedGoogle Scholar
  25. Fierro IM (2005) Angiogenesis and lipoxins. Prostaglandins Leukot Essent Fatty Acids 73:271–275PubMedGoogle Scholar
  26. Fierro IM, Kutok JL, Serhan CN (2002) Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther 300:385–392PubMedGoogle Scholar
  27. Fierro IM, Colgan SP, Bernasconi G, Petasis NA, Clish CB, Arita M, Serhan CN (2003) Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit human neutrophil migration: comparisons between synthetic 15 epimers in chemotaxis and transmigration with microvessel endothelial cells and epithelial cells. J Immunol 170:2688–2694PubMedGoogle Scholar
  28. Filep JG, Khreiss T, Jozsef L (2005) Lipoxins and aspirin-triggered lipoxins in neutrophil adhesion and signal transduction. Prostaglandins Leukot Essent Fatty Acids 73:257–262PubMedGoogle Scholar
  29. Fiore S, Ryeom SW, Weller PF, Serhan CN (1992) Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils. J Biol Chem 267:16168–16176PubMedGoogle Scholar
  30. Fiore S, Serhan CN (1990) Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils. J Exp Med 172:1451–1457PubMedGoogle Scholar
  31. Fiore S, Serhan CN (1995) Lipoxin A4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: inhibition of CD11/18 expression by lipoxin A4-lipoxin A4 receptor interaction. Biochemistry 34:16678–16686PubMedGoogle Scholar
  32. Fiore S, Maddox JF, Perez HD, Serhan CN (1994) Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J Exp Med 180:253–260PubMedGoogle Scholar
  33. Fiorucci S, de Lima OM Jr, Mencarelli A, Palazzetti B, Distrutti E, McKnight W, Dicay M, Ma L, Romano M, Morelli A, Wallace JL (2002) Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology 123:1598–1606PubMedGoogle Scholar
  34. Fiorucci S, Santucci L, Wallace JL, Sardina M, Romano M, del Soldato P, Morelli A (2003) Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci USA 100:10937–10941PubMedGoogle Scholar
  35. Fiorucci S, Wallace JL, Mencarelli A, Distrutti E, Rizzo G, Farneti S, Morelli A, Tseng JL, Suramanyam B, Guilford WJ, Parkinson JF (2004) A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci USA 101:15736–15741PubMedGoogle Scholar
  36. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–31PubMedGoogle Scholar
  37. Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267:10931–10934PubMedGoogle Scholar
  38. Gangemi S, Pescara L, D'Urbano E, Basile G, Nicita-Mauro V, Davi G, Romano M (2005) Aging is characterized by a profound reduction in anti-inflammatory lipoxin A4 levels. Exp Gerontol 40:612–614PubMedGoogle Scholar
  39. Gewirtz AT, Collier-Hyams LS, Young AN, Kucharzik T, Guilford WJ, Parkinson JF, Williams IR, Neish AS, Madara JL (2002) Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol 168:5260–5267PubMedGoogle Scholar
  40. Gilbert RE, Kelly DJ, McKay T, Chadban S, Hill PA, Cooper ME, Atkins RC, Nikolic-Paterson DJ (2001) PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 59:1324–1332PubMedGoogle Scholar
  41. Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR (2000) Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 164:1663–1667PubMedGoogle Scholar
  42. Goetzl EJ, An S, Smith WL (1995) Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases. FASEB J 9:1051–1058PubMedGoogle Scholar
  43. Goh J, Baird AW, O'Keane C, Watson RW, Cottell D, Bernasconi G, Petasis NA, Godson C, Brady HR, MacMathuna P (2001) Lipoxin A(4) and aspirin-triggered 15-epi-lipoxin A(4) antagonize TNF-alpha-stimulated neutrophil-enterocyte interactions in vitro and attenuate TNF-alpha-induced chemokine release and colonocyte apoptosis in human intestinal mucosa ex vivo. J Immunol 167:2772–2780PubMedGoogle Scholar
  44. Gronert K, Gewirtz A, Madara JL, Serhan CN (1998) Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release. J Exp Med 187:1285–1294PubMedGoogle Scholar
  45. Gronert K, Martinsson-Niskanen T, Ravasi S, Chiang N, Serhan CN (2001) Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. Am J Pathol 158:3–9PubMedGoogle Scholar
  46. Gronert K, Maheshwari N, Khan N, Hassan IR, Dunn M, Laniado Schwartzman M (2005) A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J Biol Chem 280:15267–15278PubMedGoogle Scholar
  47. Gupta AG, Hirakata A, Proia AD (1993) Effect of inhibitors of arachidonic acid metabolism on corneal reepithelialization in the rat. Exp Eye Res 56:701–708PubMedGoogle Scholar
  48. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN (2003) Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 278:14677–14687PubMedGoogle Scholar
  49. Jozsef L, Zouki C, Petasis NA, Serhan CN, Filep JG (2002) Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci USA 99:13266–13271PubMedGoogle Scholar
  50. Kantarci A, Van Dyke TE (2003) Lipoxins in chronic inflammation. Crit Rev Oral Biol Med 14:4–12PubMedGoogle Scholar
  51. Karp CL, Cooper AM (2005) An oily, sustained counter-regulatory response to TB. J Clin Invest 115:1473–1476PubMedGoogle Scholar
  52. Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME (2001) Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 12:2098–2107PubMedGoogle Scholar
  53. Kieran NE, Doran PP, Connolly SB, Greenan MC, Higgins DF, Leonard M, Godson C, Taylor CT, Henger A, Kretzler M, Burne MJ, Rabb H, Brady HR (2003) Modification of the transcriptomic response to renal ischemia/reperfusion injury by lipoxin analog. Kidney Int 64:480–492PubMedGoogle Scholar
  54. Kim SJ (1988) Formation of lipoxins by alveolar macrophages. Biochem Biophys Res Commun 150:870–876PubMedGoogle Scholar
  55. Langham RG, Kelly DJ, Maguire J, Dowling JP, Gilbert RE, Thomson NM (2003) Over-expression of platelet-derived growth factor in human diabetic nephropathy. Nephrol Dial Transplant 18:1392–1396PubMedGoogle Scholar
  56. Lassila M, Jandeleit-Dahm K, Seah KK, Smith CM, Calkin AC, Allen TJ, Cooper ME (2005) Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 16:363–373PubMedGoogle Scholar
  57. Lee TH, Horton CE, Kyan-Aung U, Haskard D, Crea AE, Spur BW (1989) Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. Clin Sci (Lond) 77:195–203Google Scholar
  58. Lee TH, Lympany P, Crea AE, Spur BW (1991) Inhibition of leukotriene B4-induced neutrophil migration by lipoxin A4: structure-function relationships. Biochem Biophys Res Commun 180:1416–1421PubMedGoogle Scholar
  59. Leonard MO, Hannan K, Burne MJ, Lappin DW, Doran P, Coleman P, Stenson C, Taylor CT, Daniels F, Godson C, Petasis NA, Rabb H, Brady HR (2002) 15-Epi-16-(para-fluorophenoxy)-lipoxin A(4)-methyl ester, a synthetic analogue of 15-epi-lipoxin A(4), is protective in experimental ischemic acute renal failure. J Am Soc Nephrol 13:1657–1662PubMedGoogle Scholar
  60. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN (2001) Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2:612–619PubMedGoogle Scholar
  61. Levy BD, De Sanctis GT, Devchand PR, Kim E, Ackerman K, Schmidt BA, Szczeklik W, Drazen JM, Serhan CN (2002) Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med 8:1018–1023PubMedGoogle Scholar
  62. Levy BD, Bonnans C, Silverman ES, Palmer LJ, Marigowda G, Israel E (2005) Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med 172:824–830PubMedGoogle Scholar
  63. Maddox JF, Serhan CN (1996) Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J Exp Med 183:137–146PubMedGoogle Scholar
  64. Maddox JF, Hachicha M, Takano T, Petasis NA, Fokin VV, Serhan CN (1997) Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J Biol Chem 272:6972–6978PubMedGoogle Scholar
  65. Maddox JF, Colgan SP, Clish CB, Petasis NA, Fokin VV, Serhan CN (1998) Lipoxin B4 regulates human monocyte/neutrophil adherence and motility: design of stable lipoxin B4 analogs with increased biologic activity. FASEB J 12:487–494PubMedGoogle Scholar
  66. Maderna P, Godson C (2005) Taking insult from injury: lipoxins and lipoxin receptor agonists and phagocytosis of apoptotic cells. Prostaglandins Leukot Essent Fatty Acids 73:179–187PubMedGoogle Scholar
  67. Maderna P, Godson C, Hannify G, Murphy M, Brady HR (2000) Influence of lipoxin A(4) and other lipoxygenase-derived eicosanoids on tissue factor expression. Am J Physiol Cell Physiol 279:C945–953PubMedGoogle Scholar
  68. Maderna P, Cottell DC, Berlasconi G, Petasis NA, Brady HR, Godson C (2002) Lipoxins induce actin reorganization in monocytes and macrophages but not in neutrophils: differential involvement of rho GTPases. Am J Pathol 160:2275–2283PubMedGoogle Scholar
  69. Maderna P, Yona S, Perretti M, Godson C (2005) Modulation of phagocytosis of apoptotic neutrophils by supernatant from dexamethasone-treated macrophages and annexin-derived peptide Ac(2–26). J Immunol 174:3727–3733PubMedGoogle Scholar
  70. Marinissen MJ, Gutkind JS (2001) G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 22:368–376PubMedGoogle Scholar
  71. Mayadas TN, Mendrick DL, Brady HR, Tang T, Papayianni A, Assmann KJ, Wagner DD, Hynes RO, Cotran RS (1996) Acute passive anti-glomerular basement membrane nephritis in P-selectin-deficient mice. Kidney Int 49:1342–1349PubMedGoogle Scholar
  72. McMahon B, Godson C (2004) Lipoxins: endogenous regulators of inflammation. Am J Physiol Renal Physiol 286:F189–201PubMedGoogle Scholar
  73. McMahon B, Stenson C, McPhillips F, Fanning A, Brady HR, Godson C (2000) Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors. J Biol Chem 275:27566–27575PubMedGoogle Scholar
  74. McMahon B, Mitchell S, Brady HR, Godson C (2001) Lipoxins: revelations on resolution. Trends Pharmacol Sci 22:391–395PubMedGoogle Scholar
  75. McMahon B, Mitchell D, Shattock R, Martin F, Brady HR, Godson C (2002) Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation. FASEB J 16:1817–1819PubMedGoogle Scholar
  76. Mitchell D, Rodgers K, Hanly J, McMahon B, Brady HR, Martin F, Godson C (2004) Lipoxins inhibit Akt/PKB activation and cell cycle progression in human mesangial cells. Am J Pathol 164:937–946PubMedGoogle Scholar
  77. Mitchell DM, O'Meara SJ, Gaffney A, Crean JKG, Kinsella BT, Godson C (2006) The Lipoxin A4 receptor is coupled to SHP-2 activation; implications for regulating growth factor receptor signaling. SubmittedGoogle Scholar
  78. Mitchell S, Thomas G, Harvey K, Cottell D, Reville K, Berlasconi G, Petasis NA, Erwig L, Rees AJ, Savill J, Brady HR, Godson C (2002) Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol 13:2497–2507PubMedGoogle Scholar
  79. Munger KA, Montero A, Fukunaga M, Uda S, Yura T, Imai E, Kaneda Y, Valdivielso JM, Badr KF (1999) Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc Natl Acad Sci USA 96:13375–13380PubMedGoogle Scholar
  80. Murakami M, Austen KF, Bingham CO 3rd, Friend DS, Penrose JF, Arm JP (1995) Interleukin-3 regulates development of the 5-lipoxygenase/leukotriene C4 synthase pathway in mouse mast cells. J Biol Chem 270:22653–22656PubMedGoogle Scholar
  81. Nakagawa H, Sasahara M, Haneda M, Koya D, Hazama F, Kikkawa R (2000) Immunohistochemical characterization of glomerular PDGF B-chain and PDGF beta-receptor expression in diabetic rats. Diabetes Res Clin Pract 48:87–98PubMedGoogle Scholar
  82. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino Y, Koide H (1993) mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 42:450–456PubMedGoogle Scholar
  83. Nassar GM, Morrow JD, Roberts LJ 2nd, Lakkis FG, Badr KF (1994) Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. J Biol Chem 269:27631–27634PubMedGoogle Scholar
  84. Ohse T, Ota T, Kieran N, Godson C, Yamada K, Tanaka T, Fujita T, Nangaku M (2004) Modulation of interferon-induced genes by lipoxin analogue in anti-glomerular basement membrane nephritis. J Am Soc Nephrol 15:919–927PubMedGoogle Scholar
  85. Papayianni A, Serhan CN, Phillips ML, Rennke HG, Brady HR (1995) Transcellular biosynthesis of lipoxin A4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis. Kidney Int 47:1295–1302PubMedGoogle Scholar
  86. Papayianni A, Serhan CN, Brady HR (1996) Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J Immunol 156:2264–22672PubMedGoogle Scholar
  87. Parente L, Perretti M (2003) Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol 65:153–159PubMedGoogle Scholar
  88. Perretti M, Chiang N, La M, Fierro IM, Marullo S, Getting SJ, Solito E, Serhan CN (2002) Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med 8:1296–1302PubMedGoogle Scholar
  89. Planaguma A, Titos E, Lopez-Parra M, Gaya J, Pueyo G, Arroyo V, Claria J (2002) Aspirin (ASA) regulates 5-lipoxygenase activity and peroxisome proliferator-activated receptor alpha-mediated CINC-1 release in rat liver cells: novel actions of lipoxin A4 (LXA4) and ASA-triggered 15-epi-LXA4. FASEB J 16:1937–1939PubMedGoogle Scholar
  90. Qiu FH, Devchand PR, Wada K, Serhan CN (2001) Aspirin-triggered lipoxin A4 and lipoxin A4 up-regulate transcriptional corepressor NAB1 in human neutrophils. FASEB J 15:2736–2738PubMedGoogle Scholar
  91. Reville K, Crean JK, Vivers S, Dransfield I, Godson C (2006) Lipoxin A4 redistributes myosin IIA and Cdc42 in macrophages: implications for phagocytosis of apoptotic leukocytes. J Immunol 176:1878–1888PubMedGoogle Scholar
  92. Ring WL, Riddick CA, Baker JR, Munafo DA, Bigby TD (1996) Lymphocytes stimulate expression of 5-lipoxygenase and its activating protein in monocytes in vitro via granulocyte macrophage colony-stimulating factor and interleukin 3. J Clin Invest 97:1293–1301PubMedGoogle Scholar
  93. Rodgers K, McMahon B, Mitchell D, Sadlier D, Godson C (2005) Lipoxin A4 modifies platelet-derived growth factor-induced pro-fibrotic gene expression in human renal mesangial cells. Am J Pathol 167:683–694PubMedGoogle Scholar
  94. Romano M, Maddox JF, Serhan CN (1996) Activation of human monocytes and the acute monocytic leukemia cell line (THP-1) by lipoxins involves unique signaling pathways for lipoxin A4 versus lipoxin B4: evidence for differential Ca2+ mobilization. J Immunol 157:2149–2154PubMedGoogle Scholar
  95. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN (1987) Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237:1171–1176PubMedGoogle Scholar
  96. Scalia R, Gefen J, Petasis NA, Serhan CN, Lefer AM (1997) Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: role of P-selectin. Proc Natl Acad Sci USA 94:9967–9972PubMedGoogle Scholar
  97. Schaldach CM, Riby J, Bjeldanes LF (1999) Lipoxin A4: a new class of ligand for the Ah receptor. Biochemistry 38:7594–7600PubMedGoogle Scholar
  98. Serhan CN (2002) Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat 68–69:433–455PubMedGoogle Scholar
  99. Serhan CN, Savill J (2005) Resolution of inflammation: the beginning programs the end. Nat Immunol 6:1191–1197PubMedGoogle Scholar
  100. Serhan CN, Sheppard KA (1990) Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J Clin Invest 85:772–780PubMedGoogle Scholar
  101. Serhan CN, Hamberg M, Samuelsson B (1984) Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci USA 81:5335–5339PubMedGoogle Scholar
  102. Serhan CN, Fiore S, Brezinski DA, Lynch S (1993) Lipoxin A4 metabolism by differentiated HL-60 cells and human monocytes: conversion to novel 15-oxo and dihydro products. Biochemistry 32:6313–6319PubMedGoogle Scholar
  103. Serhan CN, Maddox JF, Petasis NA, Akritopoulou-Zanze I, Papayianni A, Brady HR, Colgan SP, Madara JL (1995) Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 34:14609–14615PubMedGoogle Scholar
  104. Serhan CN, Haeggstrom JZ, Leslie CC (1996) Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J 10:1147–1158PubMedGoogle Scholar
  105. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K (2000) Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192:1197–1204PubMedGoogle Scholar
  106. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL (2002) Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 196:1025–1037PubMedGoogle Scholar
  107. Serhan CN, Jain A, Marleau S, Clish C, Kantarci A, Behbehani B, Colgan SP, Stahl GL, Merched A, Petasis NA, Chan L, Van Dyke TE (2003) Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol 171:6856–6865PubMedGoogle Scholar
  108. Simchowitz L, Fiore S, Serhan CN (1994) Carrier-mediated transport of lipoxin A4 in human neutrophils. Am J Physiol 267:C1525–1534PubMedGoogle Scholar
  109. Sodin-Semrl S, Taddeo B, Tseng D, Varga J, Fiore S (2000) Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J Immunol 164:2660–2666PubMedGoogle Scholar
  110. Sodin-Semrl S, Spagnolo A, Barbaro B, Varga J, Fiore S (2004a) Lipoxin A4 counteracts synergistic activation of human fibroblast-like synoviocytes. Int J Immunopathol Pharmacol 17:15–25PubMedGoogle Scholar
  111. Sodin-Semrl S, Spagnolo A, Mikus R, Barbaro B, Varga J, Fiore S (2004b) Opposing regulation of interleukin-8 and NF-kappaB responses by lipoxin A4 and serum amyloid A via the common lipoxin A receptor. Int J Immunopathol Pharmacol 17:145–156PubMedGoogle Scholar
  112. Souza MH, de Lima OM Jr, Zamuner SR, Fiorucci S, Wallace JL (2003) Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis. Am J Physiol Gastrointest Liver Physiol 285:G54–61PubMedGoogle Scholar
  113. Stankova J, Rola-Pleszczynski M, Dubois CM (1995) Granulocyte-macrophage colony-stimulating factor increases 5-lipoxygenase gene transcription and protein expression in human neutrophils. Blood 85:3719–3726PubMedGoogle Scholar
  114. Su SB, Gong W, Gao JL, Shen W, Murphy PM, Oppenheim JJ, Wang JM (1999) A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med 189:395–402PubMedGoogle Scholar
  115. Swirnoff AH, Apel ED, Svaren J, Sevetson BR, Zimonjic DB, Popescu NC, Milbrandt J (1998) Nab1, a corepressor of NGFI-A (Egr-1), contains an active transcriptional repression domain. Mol Cell Biol 18:512–524PubMedGoogle Scholar
  116. Takano T, Fiore S, Maddox JF, Brady HR, Petasis NA, Serhan CN (1997) Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J Exp Med 185:1693–1704PubMedGoogle Scholar
  117. Vachier I, Bonnans C, Chavis C, Farce M, Godard P, Bousquet J, Chanez P (2005) Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J Allergy Clin Immunol 115:55–60PubMedGoogle Scholar
  118. Vaughn MW, Proske RJ, Haviland DL (2002) Identification, cloning, and functional characterization of a murine lipoxin A4 receptor homologue gene. J Immunol 169:3363–3369PubMedGoogle Scholar
  119. Wu SH, Lu C, Dong L, Zhou GP, He ZG, Chen ZQ (2005) Lipoxin A inhibits TNF-alpha-induced production of interleukins and proliferation of rat mesangial cells. Kidney Int 68:35–46PubMedGoogle Scholar
  120. Wu SH, Wu XH, Lu C, Dong L, Zhou GP, Chen ZQ (2006) Lipoxin A4 inhibits connective tissue growth factor-induced production of chemokines in rat mesangial cells. Kidney Int 69:248–256PubMedGoogle Scholar
  121. You M, Flick LM, Yu D, Feng GS (2001) Modulation of the nuclear factor kappa B pathway by Shp-2 tyrosine phosphatase in mediating the induction of interleukin (IL)-6 by IL-1 or tumor necrosis factor. J Exp Med 193:101–110PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.School of Medicine and Medical Sciences, University College DublinUCD Conway Institute of Biomolecular and Biomedical Research and UCB Diabetes Research CenterDublin 4Ireland

Personalised recommendations